SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

NCT00121290 | Completed Phase 1

• 6 other identifiers: NCI-2009-00085CDR0000653877PHI 04536816P30CA068485U01CA099177
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

This phase I trial studies the side effects and best dose of SJG-136 in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Outcome Measures

Primary Outcomes (1)

• MTD defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity

  21 days

Secondary Outcomes (1)

• Bivariate response variable (tumor response) evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST)

  Up to 5 years

Study Arms (1)

Treatment (SJG-136)

EXPERIMENTAL

Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Drug: SJG-136; Other: laboratory biomarker analysis; Other: pharmacological study

Interventions

SJG-136 DRUG

Given IV

Treatment (SJG-136)

laboratory biomarker analysis OTHER

Correlative studies

Treatment (SJG-136)

pharmacological study OTHER

Correlative studies

Also known as: pharmacological studies

Treatment (SJG-136)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
• Prior chemotherapy or immunotherapy allowed
• Time interval must be at least 4 weeks since prior chemotherapy or immunotherapy, 6 weeks if the last regimen included BCNU or mitomycin C
• Radiation therapy to \< 25% of hematopoietic bone marrow is allowed
• ECOG performance status =\<2 (Karnofsky \>= 60%)
• Life expectancy of greater than three months
• Recovered from prior therapy
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
• Ability to understand and the willingness to sign a written informed consent document
• WBC \>= 3,000/mm\^3
• Absolute neutrophil count \>= 1,500/mm\^3
• Platelet count \>= 100,000/mm\^3
• Bilirubin normal
• AST and ALT =\< 2.5 times upper limit of normal
• Creatinine =\< 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min

You may not qualify if:

• Patients receiving any other investigational agents
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study
• Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with SJG-136, breastfeeding should be discontinued if the mother is treated with SJG-136
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to SJG-136
• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with SJG-136
• With the exception of alopecia (and other situations in which the organ dysfunction or symptoms are considered clinically insignificant or irrelevant to this study), patients may not have baseline organ dysfunction or symptoms that qualify as Grade 2 or greater by CTC AE v. 3.0
• No other chemotherapy, immunotherapy, radiation therapy, surgery for cancer (including resection of any metastases), specific antitumor therapy, or experimental medications will be permitted while the patients are participating in this study
• Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Palliative radiation therapy is not allowed

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (1)

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Interventions

1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione)

Study Officials

• Igor Puzanov

  Vanderbilt-Ingram Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 19, 2005
• First Posted: July 21, 2005
• Study Start: February 1, 2005
• Primary Completion: April 1, 2008
• Last Updated: February 24, 2014

Record last verified: 2013-04

Locations

US (1)